Do anticoagulants improve survival in patients with cancer?;Les anticoagulants allongent-ils la survie des patients cancéreux ?

Pathologie Biologie

Volumn 56, Issue 4, 2008, Pages 233-238

  Meyer, G ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Anticoagulants; Cancer; Heparin; Low molecular weight heparin; Metastasis; Survival

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; SELECTIN; TINZAPARIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTICOAGULATION; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CELL SURFACE; CLINICAL TRIAL; DRUG DOSE REDUCTION; EXTRACELLULAR MATRIX; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS INHIBITION; OVERALL SURVIVAL; PANCREAS CANCER; PROGNOSIS; PROPHYLAXIS; RETROSPECTIVE STUDY; REVIEW; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTE ADHESION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DISEASE PROGRESSION; HEMOSTASIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 44549084369     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.03.001     Document Type: Review

References (34)

1. Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 78 1 (1997 Jul) 117-120
2. Rickles F.R., Patierno S., and Fernandez P.M. Tissue factor, thrombin, and cancer. Chest 124 Suppl. 3 (2003 Sep) 58S-68S
3. Koomagi R., and Volm M. Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 79 1 (1998 Feb) 19-22
4. Mousa S.A., and Mohamed S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anticancer efficacy. Oncol Rep 12 4 (2004 Oct) 683-688
5. Nierodzik M.L., Kajumo F., and Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 52 12 (1992 Jun) 3267-3272
6. Nierodzik M.L., Plotkin A., Kajumo F., and Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 87 1 (1991 Jan) 229-236
7. Nagy J.A., Brown L.F., Senger D.R., Lanir N., Van de Water L., Dvorak A.M., et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 948 3 (1989 Feb) 305-326
8. Bennett M.R., Evan G.I., and Newby A.C. Deregulated expression of the c-myc oncogene abolishes inhibition of proliferation of rat vascular smooth muscle cells by serum reduction, interferon-gamma, heparin, and cyclic nucleotide analogues and induces apoptosis. Circ Res 74 3 (1994 Mar) 525-536
9. Cavari S., Ruggiero M., and Vannucchi S. Antiproliferative effects of heparin on normal and transformed NIH/3T3 fibroblasts. Cell Biol Int 17 8 (1993 Aug) 781-786
10. Granerus M., and Engstrom W. Growth factors and apoptosis. Cell Prolif 29 6 (1996 Jun) 309-314
11. Lwaleed B.A., and Cooper A.J. Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu. Med Hypotheses 55 6 (2000 Dec) 470-473
12. Nakasaki T., Wada H., Shigemori C., Miki C., Gabazza E.C., Nobori T., et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 69 4 (2002 Apr) 247-254
13. Mousa S.A., and Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 92 3 (2004 Sep) 627-633
14. Amirkhosravi A., Mousa S.A., Amaya M., and Francis J.L. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 1 9 (2003 Sep) 1972-1976
15. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., and Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98 6 (2001 Mar 13) 3352-3357
16. Ludwig R.J., Boehme B., Podda M., Henschler R., Jager E., Tandi C., et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 64 8 (2004 Apr 15) 2743-2750
17. Stevenson J.L., Choi S.H., and Varki A. Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 11 19 Pt 1 (2005 Oct 1) 7003-7011
18. Antachopoulos C.T., Iliopoulos D.C., Gagos S., Agapitos M.V., Karayannacos P.E., Roboli S.K., et al. In vitro effects of heparin on SW480 tumor cell-matrix interaction. Anticancer Res 15 4 (1995 Jul-Aug) 1411-1416
19. Bertolesi G.E., Farias E.F., Alonso D.F., Bal de Kier Joffe E., Lauria de Cidre S., and Eijan A.M. Insight into the profibrinolytic activity of heparin: effects on the activation of plasminogen mediated by urokinase. Blood Coagul Fibrinolysis 8 7 (1997 Oct) 403-410
20. Vlodavsky I., Mohsen M., Lider O., Svahn C.M., Ekre H.P., Vigoda M., et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis 14 1-6 (1994) 290-302
21. Kenagy R.D., Nikkari S.T., Welgus H.G., and Clowes A.W. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells. J Clin Invest 93 5 (1994 May) 1987-1993
22. Westermarck J., and Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. Faseb J. 13 8 (1999 May) 781-792
23. Pross M., Lippert H., Misselwitz F., Nestler G., Kruger S., Langer H., et al. Low-molecular-weight heparin (reviparin) diminishes tumor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy. Thromb Res 110 4 (2003 Jun) 215-220
24. Smorenburg S.M., Vink R., Otten H.M., Swaneveld F., and Buller H.R. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86 6 (2001 Dec) 1586-1587
25. Smorenburg S.M., Hettiarachchi R.J., Vink R., and Buller H.R. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review. Thromb Haemost 82 6 (1999 Dec) 1600-1604
26. Lebeau B., Chastang C., Brechot J.M., Capron F., Dautzenberg B., Delaisements C., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74 1 (1994 Jul) 38-45
27. Gould M.K., Dembitzer A.D., Sanders G.D., and Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 130 10 (1999 May) 789-799
28. Green D., Hull R.D., Brant R., and Pineo G.F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 339 8807 (1992 Jun) 1476
29. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., Levine M., Prins M.H., and Buller H.R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82 2 (1999 Aug) 947-952
30. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 10 (2004 May) 1944-1948
31. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 8 (2004 Aug) 1266-1271
32. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 10 (2005 Apr) 2130-2135
33. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (2003 Jul) 146-153
34. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 10 (2005 Apr) 2123-2129